“It’s the pill in the hamburger approach.” — Andrew Kates, MD, of Washington University School of Medicine in St. Louis, discussing a trial that swapped in lower-sodium table salt across entire communities to control hypertension.

“I don’t understand where the ‘there’ is on this.” — Medicare Payment Advisory Commission (MedPAC) member Marge Ginsburg, BSN, MPH, of Sacramento, California, on an analysis about the “spillover” effect of Medicare Advantage plans on spending and coding in fee-for-service Medicare.

“I think has the potential to be transformative for how we think about prevention.” — Donald Lloyd-Jones, MD, of Northwestern University Feinberg School of Medicine in Chicago, discussing how an investigational drug could lower LDL cholesterol in certain patients.

“In that respect it’s something of a landmark trial.” — Tina Alster, MD, director of the Washington Institute of Dermatologic Laser Surgery in Washington, D.C., on a trial comparing three treatments for patients with varicose veins.

“He had the million-dollar work-up, but we found nothing that could explain what was happening with him.” — Karen Schultz, MD, a pediatric pulmonologist at Fort Worth’s Cook Children’s Medical Center in Texas, discussing a teenage patient who became seriously ill after vaping.

“It’s like a sentinel flag, not every one will show it.” — Salim Yusuf, MD, PhD, of Health Research Institute at McMaster University in Hamilton, Ontario, on the shift of cause of death in high income countries from cardiovascular disease to cancer.

“We need to be very careful with that.” — Alexei A. Grom, MD, of Cincinnati Children’s Hospital Medical Center, on the idea of a link between biologic exposure and a new lung disease in patients with a certain kind of arthritis.

“From a public health perspective it is more important to have a generic answer than a specific one.” — Trisha M. Perl, MD, of UT Southwestern Medical Center in Dallas, on a trial that found regular masks could prevent flu in healthcare workers.